Suppr超能文献

相似文献

1
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy.
Nat Rev Immunol. 2017 Sep;17(9):559-572. doi: 10.1038/nri.2017.49. Epub 2017 May 30.
2
CCL7 Signaling in the Tumor Microenvironment.
Adv Exp Med Biol. 2020;1231:33-43. doi: 10.1007/978-3-030-36667-4_4.
3
The chemokine network: a target in cancer biology?
Adv Drug Deliv Rev. 2006 Oct 1;58(8):962-74. doi: 10.1016/j.addr.2006.03.012. Epub 2006 Aug 15.
4
Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy.
Int J Mol Sci. 2021 Sep 10;22(18):9804. doi: 10.3390/ijms22189804.
5
Chemokine systems in oncology: From microenvironment modulation to nanocarrier innovations.
Int J Biol Macromol. 2024 May;268(Pt 1):131679. doi: 10.1016/j.ijbiomac.2024.131679. Epub 2024 Apr 17.
6
Improving homing in T cell therapy.
Cytokine Growth Factor Rev. 2017 Aug;36:107-116. doi: 10.1016/j.cytogfr.2017.06.009. Epub 2017 Jun 23.
8
Role of chemokine receptors in thyroid cancer and immunotherapy.
Endocr Relat Cancer. 2019 Aug;26(8):R465-R478. doi: 10.1530/ERC-19-0163.
9
Chemokines in cancer.
Cancer Immunol Res. 2014 Dec;2(12):1125-31. doi: 10.1158/2326-6066.CIR-14-0160.
10
Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor.
Mol Immunol. 2020 Jan;117:201-215. doi: 10.1016/j.molimm.2019.11.014. Epub 2019 Dec 10.

引用本文的文献

2
SMC2 as a potential prognostic biomarker in lung adenocarcinoma and its correlation with immune microenvironment.
Mol Clin Oncol. 2025 Aug 12;23(4):93. doi: 10.3892/mco.2025.2888. eCollection 2025 Oct.
4
Chemokines: humble yet mighty players in the tumour microenvironment.
Front Immunol. 2025 Aug 7;16:1601756. doi: 10.3389/fimmu.2025.1601756. eCollection 2025.
5
Targeting STING to disrupt macrophage-mediated adhesion in encapsulating peritoneal sclerosis.
Commun Biol. 2025 Aug 23;8(1):1266. doi: 10.1038/s42003-025-08662-z.
6
Overcoming immunotherapy resistance in bladder cancer with a novel antibody-drug conjugate RC48.
J Immunother Cancer. 2025 Aug 11;13(8):e011881. doi: 10.1136/jitc-2025-011881.
7
Predicting head and neck cancer response to radiotherapy with a chemokine-based model.
Sci Rep. 2025 Aug 4;15(1):28450. doi: 10.1038/s41598-025-13346-z.
8
Biased antagonism of a series of bicyclic CXCR2 intracellular allosteric modulators.
Front Pharmacol. 2025 Jul 14;16:1631129. doi: 10.3389/fphar.2025.1631129. eCollection 2025.
9
Inhibition of FAK promotes pancreatic cancer immunotherapy by mediating CXCL10 secretion to enhance CD8 T cell infiltration.
Oncoimmunology. 2025 Dec;14(1):2539442. doi: 10.1080/2162402X.2025.2539442. Epub 2025 Jul 28.

本文引用的文献

1
Inflammatory regulatory T cells in the microenvironments of ulcerative colitis and colon carcinoma.
Oncoimmunology. 2016 Aug 12;5(8):e1105430. doi: 10.1080/2162402X.2015.1105430. eCollection 2016 Aug.
2
Th22 cells control colon tumorigenesis through STAT3 and Polycomb Repression complex 2 signaling.
Oncoimmunology. 2015 Sep 2;5(8):e1082704. doi: 10.1080/2162402X.2015.1082704. eCollection 2016 Aug.
3
Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling.
Cancer Res. 2016 Jun 1;76(11):3156-65. doi: 10.1158/0008-5472.CAN-15-2528. Epub 2016 Apr 6.
4
Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer.
Cell. 2016 May 19;165(5):1092-1105. doi: 10.1016/j.cell.2016.04.009. Epub 2016 Apr 28.
5
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.
Sci Transl Med. 2016 Mar 2;8(328):328rv4. doi: 10.1126/scitranslmed.aad7118.
6
Biological and pathological activities of interleukin-22.
J Mol Med (Berl). 2016 May;94(5):523-34. doi: 10.1007/s00109-016-1391-6. Epub 2016 Feb 29.
7
Ectopic expression of the chemokine CXCL17 in colon cancer cells.
Br J Cancer. 2016 Mar 15;114(6):697-703. doi: 10.1038/bjc.2016.4. Epub 2016 Feb 18.
8
CCR9 in cancer: oncogenic role and therapeutic targeting.
J Hematol Oncol. 2016 Feb 16;9:10. doi: 10.1186/s13045-016-0236-7.
9
PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer.
Cancer Res. 2016 Jan 15;76(2):275-82. doi: 10.1158/0008-5472.CAN-15-1938. Epub 2015 Nov 13.
10
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
Science. 2015 Nov 27;350(6264):1079-84. doi: 10.1126/science.aad1329. Epub 2015 Nov 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验